company background image
VXRT

Vaxart NasdaqCM:VXRT Stock Report

Last Price

US$1.28

Market Cap

US$168.0m

7D

-5.9%

1Y

-82.9%

Updated

25 Nov, 2022

Data

Company Financials +
VXRT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

VXRT Stock Overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

Vaxart, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share PriceUS$1.28
52 Week HighUS$8.13
52 Week LowUS$1.26
Beta0.79
1 Month Change-24.71%
3 Month Change-58.17%
1 Year Change-82.89%
3 Year Change293.85%
5 Year Changen/a
Change since IPO-84.94%

Recent News & Updates

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Recent updates

Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

Aug 25
Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely

May 11
We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely

Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%

Mar 03
Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%

We're Interested To See How Vaxart (NASDAQ:VXRT) Uses Its Cash Hoard To Grow

Feb 10
We're Interested To See How Vaxart (NASDAQ:VXRT) Uses Its Cash Hoard To Grow

How Much Of Vaxart, Inc. (NASDAQ:VXRT) Do Institutions Own?

Jan 20
How Much Of Vaxart, Inc. (NASDAQ:VXRT) Do Institutions Own?

Market Sentiment Around Loss-Making Vaxart, Inc. (NASDAQ:VXRT)

Dec 22
Market Sentiment Around Loss-Making Vaxart, Inc. (NASDAQ:VXRT)

Wouter Latour Is The Chairman of Vaxart, Inc. (NASDAQ:VXRT) And They Just Sold 100% Of Their Shares

Nov 26
Wouter Latour Is The Chairman of Vaxart, Inc. (NASDAQ:VXRT) And They Just Sold 100% Of Their Shares

What Does The Future Hold For Vaxart, Inc. (NASDAQ:VXRT)? These Analysts Have Been Cutting Their Estimates

Nov 19
What Does The Future Hold For Vaxart, Inc. (NASDAQ:VXRT)? These Analysts Have Been Cutting Their Estimates

Shareholder Returns

VXRTUS BiotechsUS Market
7D-5.9%0.4%1.3%
1Y-82.9%-14.4%-18.5%

Return vs Industry: VXRT underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: VXRT underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is VXRT's price volatile compared to industry and market?
VXRT volatility
VXRT Average Weekly Movement11.8%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: VXRT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: VXRT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a110Andy Floroiuhttps://vaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Vaxart, Inc. Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
VXRT fundamental statistics
Market CapUS$168.00m
Earnings (TTM)-US$104.60m
Revenue (TTM)US$159.00k

1,058x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VXRT income statement (TTM)
RevenueUS$159.00k
Cost of RevenueUS$76.13m
Gross Profit-US$75.97m
Other ExpensesUS$28.64m
Earnings-US$104.60m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.80
Gross Margin-47,777.36%
Net Profit Margin-65,788.68%
Debt/Equity Ratio0%

How did VXRT perform over the long term?

See historical performance and comparison